Cargando…
Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer
Studies have shown cell-free microRNA (miRNA) circulating in the serum and plasma with specific expression in cancer, indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy. This study was to investigate whether plasma miRNA-21 (miR-21) can be used as a biomarker for...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sun Yat-sen University Cancer Center
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013415/ https://www.ncbi.nlm.nih.gov/pubmed/21627863 http://dx.doi.org/10.5732/cjc.010.10522 |
_version_ | 1782315046856032256 |
---|---|
author | Wei, Juan Gao, Wen Zhu, Cheng-Jun Liu, Yi-Qian Mei, Zhu Cheng, Ting Shu, Yong-Qian |
author_facet | Wei, Juan Gao, Wen Zhu, Cheng-Jun Liu, Yi-Qian Mei, Zhu Cheng, Ting Shu, Yong-Qian |
author_sort | Wei, Juan |
collection | PubMed |
description | Studies have shown cell-free microRNA (miRNA) circulating in the serum and plasma with specific expression in cancer, indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy. This study was to investigate whether plasma miRNA-21 (miR-21) can be used as a biomarker for the early detection of non–small cell lung cancer (NSCLC) and to explore its association with clinicopathologic features and sensitivity to platinum-based chemotherapy. We used real-time RT-PCR to investigate the expression of miR-21 in the plasma of 63 NSCLC patients and 30 healthy controls and correlated the findings with early diagnosis, pathologic parameters, and treatment. Thirty-five patients (stages NIB and IV) were evaluable for chemotherapeutic responses: 11 had partial response (PR); 24 had stable and progressive disease (SD+ PD). Plasma miR-21 was significantly higher in NSCLC patients than in age- and sex-matched controls (P < 0.001). miR-21 was related to TNM stage (P < 0.001), but not related to age, sex, smoking status, histological classification, lymph node status, and metastasis (all P > 0.05). This marker yielded a receiver operating characteristic (ROC) curve area of 0.775 (95% CI: 0.681 – 0.868) with 76.2% sensitivity and 70.0% specificity. Importantly, miR-21 plasma levels in PR samples were several folds lower than that in SD plus PD samples (P = 0.049), and were close to that in healthy controls (P = 0.130). Plasma miR-21 can serve as a circulating tumor biomarker for the early diagnosis of NSCLC and is related to the sensitivity to platinum-base chemotherapy. |
format | Online Article Text |
id | pubmed-4013415 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Sun Yat-sen University Cancer Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-40134152014-05-15 Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer Wei, Juan Gao, Wen Zhu, Cheng-Jun Liu, Yi-Qian Mei, Zhu Cheng, Ting Shu, Yong-Qian Chin J Cancer Original Article Studies have shown cell-free microRNA (miRNA) circulating in the serum and plasma with specific expression in cancer, indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy. This study was to investigate whether plasma miRNA-21 (miR-21) can be used as a biomarker for the early detection of non–small cell lung cancer (NSCLC) and to explore its association with clinicopathologic features and sensitivity to platinum-based chemotherapy. We used real-time RT-PCR to investigate the expression of miR-21 in the plasma of 63 NSCLC patients and 30 healthy controls and correlated the findings with early diagnosis, pathologic parameters, and treatment. Thirty-five patients (stages NIB and IV) were evaluable for chemotherapeutic responses: 11 had partial response (PR); 24 had stable and progressive disease (SD+ PD). Plasma miR-21 was significantly higher in NSCLC patients than in age- and sex-matched controls (P < 0.001). miR-21 was related to TNM stage (P < 0.001), but not related to age, sex, smoking status, histological classification, lymph node status, and metastasis (all P > 0.05). This marker yielded a receiver operating characteristic (ROC) curve area of 0.775 (95% CI: 0.681 – 0.868) with 76.2% sensitivity and 70.0% specificity. Importantly, miR-21 plasma levels in PR samples were several folds lower than that in SD plus PD samples (P = 0.049), and were close to that in healthy controls (P = 0.130). Plasma miR-21 can serve as a circulating tumor biomarker for the early diagnosis of NSCLC and is related to the sensitivity to platinum-base chemotherapy. Sun Yat-sen University Cancer Center 2011-06 /pmc/articles/PMC4013415/ /pubmed/21627863 http://dx.doi.org/10.5732/cjc.010.10522 Text en Chinese Journal of Cancer http://creativecommons.org/licenses/by-nc-sa/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License, which allows readers to alter, transform, or build upon the article and then distribute the resulting work under the same or similar license to this one. The work must be attributed back to the original author and commercial use is not permitted without specific permission. |
spellingShingle | Original Article Wei, Juan Gao, Wen Zhu, Cheng-Jun Liu, Yi-Qian Mei, Zhu Cheng, Ting Shu, Yong-Qian Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer |
title | Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer |
title_full | Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer |
title_fullStr | Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer |
title_full_unstemmed | Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer |
title_short | Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer |
title_sort | identification of plasma microrna-21 as a biomarker for early detection and chemosensitivity of non–small cell lung cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013415/ https://www.ncbi.nlm.nih.gov/pubmed/21627863 http://dx.doi.org/10.5732/cjc.010.10522 |
work_keys_str_mv | AT weijuan identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer AT gaowen identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer AT zhuchengjun identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer AT liuyiqian identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer AT meizhu identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer AT chengting identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer AT shuyongqian identificationofplasmamicrorna21asabiomarkerforearlydetectionandchemosensitivityofnonsmallcelllungcancer |